Cirrhosis/Liver Failure News

VIENNA — Emricasan missed its primary endpoint of hepatic venous pressure gradient reduction in all patients with nonalcoholic steatohepatitis-related compensated cirrhosis and severe portal hypertension but showed meaningful reductions in portal pressure among patients with high-risk disease, according to a presentation at the International Liver Congress 2019.

VIENNA — Fecal microbiota transplant, delivered via capsule, lessened hospitalizations for patients with hepatic encephalopathy while improving cognitive function, according to data presented during the International Liver Congress 2019.

VIENNA — In this exclusive video from the International Liver Congress 2019, Elliot B. Tapper, MD, from the University of Michigan, discusses understanding and reducing risks for hospital readmission in patients with compensated cirrhosis and acute-on-chronic liver failure.

Can-Fite BioPharma announced that the phase 2 study of their advanced liver cancer candidate, Namodenoson, did not achieve its primary endpoint of overall survival, according to a press release.

Many chronic liver complications such as autoimmune hepatitis and nonalcoholic fatty liver disease do not have approved therapies for direct treatment, but the current hepatology pipeline includes several candidates that have recently demonstrated safety in early trials and some that met top-line phase 3 results.

Researchers identified alterations in the skin microbiome of patients with cirrhosis that correlated with itching intensity and itch modulators, according to a recently published study.

According to a study published in Hepatology, small dense LDL cholesterol independently predicted cardiovascular disease events among liver transplant recipients, according to a study published in Hepatology.

Most gastroenterologists and hepatologists felt that the key barriers to palliative care for patients with end-stage liver disease included perception of palliative care and unrealistic expectations about prognosis, according to results of a recent survey.

Diet and lifestyle are tied closely with liver health both as risk factors for complications such as nonalcoholic fatty liver disease and as the best intervention in the case of fatty liver development and progression.

Between 2003 and 2016, liver graft loss and mortality rates among recipients of grafts from older donors improved; however, discard rates of older donor grafts continued to increase and use of older donor grafts decreased, according to a study published in JAMA Surgery.